Portola Pharmaceuticals Inc. (NASDAQ:PTLA) was up 3.9% during mid-day trading on Monday . The company traded as high as $27.56 and last traded at $26.97, with a volume of 495,337 shares trading hands. The stock had previously closed at $25.96.

A number of equities research analysts have recently issued reports on PTLA shares. Morgan Stanley cut their price target on shares of Portola Pharmaceuticals from $71.00 to $70.00 in a report on Friday, April 8th. Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 13th. Citigroup Inc. boosted their price target on shares of Portola Pharmaceuticals from $29.00 to $36.00 and gave the company a “buy” rating in a report on Friday, May 27th. Finally, Credit Suisse Group AG lowered shares of Portola Pharmaceuticals from an “outperform” rating to a “neutral” rating and cut their price target for the company from $33.00 to $30.00 in a report on Tuesday, May 31st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $41.07.

The company’s market cap is $1.51 billion. The firm’s 50-day moving average is $24.16 and its 200-day moving average is $26.83.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.06) by $0.09. The company had revenue of $8.30 million for the quarter, compared to analyst estimates of $7.91 million. Portola Pharmaceuticals’s revenue was up 245.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.95) earnings per share. Equities research analysts expect that Portola Pharmaceuticals Inc. will post ($5.17) earnings per share for the current year.

A number of hedge funds and institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its position in Portola Pharmaceuticals by 31.1% in the fourth quarter. Jennison Associates LLC now owns 858,523 shares of the biopharmaceutical company’s stock valued at $44,171,000 after buying an additional 203,505 shares during the last quarter. Wells Fargo & Company MN raised its position in Portola Pharmaceuticals by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 293,921 shares of the biopharmaceutical company’s stock valued at $15,121,000 after buying an additional 10,544 shares during the last quarter. Morgan Stanley raised its position in Portola Pharmaceuticals by 7.2% in the fourth quarter. Morgan Stanley now owns 234,948 shares of the biopharmaceutical company’s stock valued at $12,089,000 after buying an additional 15,853 shares during the last quarter. Swiss National Bank raised its position in Portola Pharmaceuticals by 20.6% in the fourth quarter. Swiss National Bank now owns 70,300 shares of the biopharmaceutical company’s stock valued at $3,617,000 after buying an additional 12,000 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Portola Pharmaceuticals by 3.6% in the fourth quarter. New York State Common Retirement Fund now owns 68,123 shares of the biopharmaceutical company’s stock valued at $3,505,000 after buying an additional 2,376 shares during the last quarter.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.